CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00748657
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:13.689669+00:00
Published At: 2015-06-10T00:00:00+00:00
Record Updated At: 2019-07-23
Results Posted At: 2015-06-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Malignant Ovarian Epithelial Tumor", "Ovarian Granulosa Cell Tumor", "Ovarian Gynandroblastoma", "Ovarian Sertoli-Leydig Cell Tumor", "Ovarian Sex Cord Tumor With Annular Tubules", "Ovarian Sex Cord-Stromal Tumor", "Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types", "Ovarian Steroid Cell Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-07-23"
protocolSection.identificationModule.nctId: "NCT00748657"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2015-06-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.